2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) that represents one of the first causes of neurological disability in young adults. Although the pathogenesis of MS is still unclear, an autoimmune mechanism has been demonstrated. According to this evidence in the last 15 years different treatments acting on the immune system have been developed. Current disease-modifying drugs (DMDs) for MS require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Moreover the clinical efficacy of these disease-modifying drugs is suboptimal. Thus, there is an important need for the development of new therapeutic strategies. Several oral therapies (fingolimod, fumaric acid, teriflunomide, laquinimod) are in development; Among these cladribine is the only therapy with the potential for short-course dosing. Cladribine is an immunosuppressant that offers sustained regulation of the immune system through a preferential lymphocyte depleting action. Cladribine has a well-characterized and well-known safety profile, derived from more than 15 years of use of the parenteral formulation both in the oncology field and in MS. This paper reviews the new oral emerging treatments and presents the available data about the use of cladribine in MS and the future perspective of its clinical use.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2010
          2010
          7 September 2010
          : 6
          : 391-399
          Affiliations
          [1 ]Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy;
          [2 ]Department of Neurological Sciences, University of Rome “La Sapienza”, Italy
          Author notes
          Correspondence: C Gasperini, Dipartimento Testa Collo, Azienda Ospedaliera S Camillo-Forlanini, Circonvallazione Gianicolense, 87, 00152 Rome, Italy, Tel +39 6 58704272, Fax +39 6 58704650, Email c.gasperini@ 123456libero.it
          Article
          tcrm-6-391
          2940747
          20856685
          © 2010 Gasperini et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          oral therapy, disease modifying drugs, multiple sclerosis, cladribine, treatment adherence

          Comments

          Comment on this article